TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Traws Pharma Inc is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of positive financial performance, absence of strong trading signals, and neutral sentiment from hedge funds and insiders suggest waiting for more favorable conditions or significant catalysts before investing.
The technical indicators are bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 41.628, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 1.724, with key support at 1.449 and resistance at 1.999.
Analysts have initiated coverage with Buy ratings and high price targets ($6.50 and $8), citing the potential of the company's pipeline, including oral antivirals for COVID-19 and influenza.
The company's financial performance is poor, with revenue dropping to zero and significant declines in net income (-64.19% YoY) and EPS (-96.14% YoY). There are no recent news catalysts, and hedge funds and insiders remain neutral.
In Q3 2025, Traws Pharma reported a 100% decline in revenue, a 64.19% YoY drop in net income to -$3,035,000, and a 96.14% YoY drop in EPS to -0.34. Gross margin remained at 100%, unchanged YoY.
Analysts from Ladenburg and H.C. Wainwright have initiated Buy ratings with price targets of $6.50 and $8, respectively, citing the potential of the company's drug pipeline to unlock shareholder value.
